Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population

详细信息    查看全文

• 作者：Junkai Li ; Xiaoyan Zuo ; Xiaoyan Lv ; Fanjun Kong ; Wen Xu ; Shujuan Yang
• 关键词：ERCC1 ; XPF ; Gastric cancer ; Response ; Oxaliplatin/5 ; Fu ; survival
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：35
• 期：8
• 页码：7569-7574
• 全文大小：132 KB
• 参考文献：1. International Agency for Research on Cancer (IARC). Globocan 2008: Stomach cancer incidence, mortality and prevalence worldwide in 2008. IARC.
  2. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 2004;54 Suppl 1:S4-1.
  3. W?hrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004;15(11):1585-5. CrossRef
  4. Tuteja N, Tuteja R. Unraveling DNA repair in human: molecular mechanisms and consequences of repair defect. Crit Rev Biochem Mol Biol. 2001;36(3):261-0. CrossRef
  5. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010;30(9):3223-2.
  6. Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst). 2010;9(7):745-3.
  7. Wang AT, Sengerová B, Cattell E, et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev. 2011;25(17):1859-0. CrossRef
  8. McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 2012;40(20):9990-0004. CrossRef
  9. Jagdis A, Phan T, Klimowicz AC, et al. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. Int J Radiat Oncol Biol Phys. 2013;85(5):1340-. CrossRef
  10. Li J, Zhang J, Liu Y, Ye G. Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer. Med Sci Monit. 2012;18(4):BR156-2. CrossRef
  11. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102(11):1600-. CrossRef
  12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-4. CrossRef
  13. Gustavsson B, Kaiser C, Carlsson G, et al. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer. 2009;124(5):1220-. CrossRef
  14. Liang J, Li QF, Yao RY, et al. Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy. Zhonghua Zhong Liu Za Zhi. 2010;32(7):515-.
  15. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol. 2012;12:137. CrossRef
  16. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331-4. CrossRef
  17. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513-0.
  18. Lu ZM, Luo TH, Nie MM, et al. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Tumour Biol. 2013 Dec 8.
  19. Metzger R, Warnecke-Eberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16(1):26-4. discussion 34. CrossRef
  20. Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011;104(7):1126-4. CrossRef
  21. Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D, et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Pharmacogenet Genom. 2013;23(11):597-04. CrossRef
  22. Chu H, Gu D, Xu M, et al. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. Mutagenesis. 2013;28(4):441-. CrossRef
  23. Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17(6):1632-0. CrossRef
  24. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T. ERCC1/XPF removes the 3-overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell. 2003;12(6):1489-8. CrossRef
  25. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, Sturgis EM. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys. 2005;62(3):665-1. CrossRef
  26. Alexander BM, Wang XZ, Niemierko A, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):164-1. CrossRef
  
• 作者单位：Junkai Li (1)
  Xiaoyan Zuo (1)
  Xiaoyan Lv (2)
  Fanjun Kong (1)
  Wen Xu (1)
  Shujuan Yang (3)
  
  1. Department of Oncology, The 456th Hospital of PAL, Jinan, 250031, China
  2. Department of Radiotherapy, Jinan Military General Hospital, Jinan, 250031, China
  3. Department of Health and Social Behavior, West China School of Public Health, Sichuan University, Chengdu, China
  
• ISSN：1423-0380

文摘

We conducted a study to investigate the role of excision repair cross-complimentary group 1 gene (ERCC1)–xeroderma pigmentosum complementation group F (XPF) gene polymorphisms in response to chemotherapy and clinical outcome of gastric patients. Three SNPs in ERCC1 (rs11615, rs3212986, and rs2298881) and two SNPs in XPF (rs2276465 and rs6498486) were extracted using Tiangen DNA kit (Tiangen Biotech, Beijing, China) according to the manufacturer’s instructions. The median follow-up time was 36.4?months, and ranged from 2-0?months. During the follow-up period, 112 patients died from gastric cancer. Individuals carrying ERCC1 rs11615 AA and XPF rs6498486 CC genotypes were associated with poorer response to chemotherapy when compared with wild-type genotype, with the ORs (95?% CI) of 0.48 (0.25-.94) and 0.38 (0.14-.00). In the Cox proportional hazards model, individuals carrying ERCC1 rs11615 GA and AA genotype had 1.91 and 2.66 risk of death when compared with those carrying GG genotype. Patients carrying the XPF rs6498486 AC and CC genotype were associate with 2.17 and 4.91-fold risk of death when compared with wild-type genotype. In conclusion, we found that ERCC1 rs11615 and XPF rs2276465 may substantially contribute to the future design of individualized cancer treatment in gastric cancer patients.